Page last updated: 2024-12-08

7-dehydrocholesterol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID439423
CHEMBL ID1797131
CHEBI ID17759
SCHEMBL ID3447
MeSH IDM0066889

Synonyms (79)

Synonym
5,7-cholestadien-3-beta-ol
CHEBI:17759 ,
(3beta)-cholesta-5,7-dien-3-ol
5,7-cholestadien-3beta-ol
cholesta-5,7-dien-3-ol, (3.beta.)-
5,7-cholestandien-3beta-ol
delta(sup 5,7)-cholesterol
delta5,7-cholesterol
cholesta-5,7-dien-3-ol, (3beta)-
caswell no. 902e
cholesta-5,7-dien-3-ol
nsc 18159
delta7-cholesterol
epa pesticide chemical code 208700
dehydrocholesterin [german]
delta(sup 7)-cholesterol
einecs 207-100-5
provitamin d(sub 3)
cholesta-5,7-dien-3-beta-ol
(3-beta)-cholesta-5,7-dien-3-ol
cholesta-5,7-dien-3-ol, (3-beta)-
nsc-18159
cholesterol, 7-dehydro-
cholesta-5,7-dien-3.beta.-ol
7-dehydrocholesterin
dehydrocholesterol
7,8-didehydrocholesterol
cholesta-5,7-dien-3beta-ol
434-16-2
7-dehydrocholesterol ,
C01164
provitamin d3
LMST01010069
7-dhc
cholesta-5,7-dien-3 beta-ol
7-dehydro-cholesterol
7-dehydrocholesterol, >=95.0% (hplc)
(3s,9s,10r,13r,14r,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
10,13-dimethyl-17-(6-methylheptan-2-yl)-2,3,4,9,11,12,14,15,16,17-decahydro-1h-cyclopenta[a]phenanthren-3-ol
CHEMBL1797131
bk1iu07gkf ,
ec 207-100-5
dehydrocholesterin
unii-bk1iu07gkf
7-dehydrocholesterol [inci]
9.beta.,10.alpha.-cholesta-5,7-dien-3.beta.-ol
cholecalciferol impurity b [ep impurity]
(3.beta.)-7-dehydrocholesterol [mi]
(-)-7-dehydrocholesterol
S5386
SCHEMBL3447
W-106230
cholesta-5,7-dien-3-ol, (3b)-
cholesta-5,7-dien-3-ol #
.delta.5,7-cholestadien-3.beta.-ol
5,7-cholestadien-3-.beta.-ol
mfcd00003624
AS-59257
F20429
cholesta-5,7-dien-3beta-ol (7,8-didehydrocholesterol; provitamin d3)
cholesta-5,7-dien-3b-ol
delta5,7-cholestadien-3beta-ol
cholesta-5,7-dien-3 beta -ol
(3b)-cholesta-5,7-dien-3-ol
7dhc
7,8-dehydro-cholesterol
5,7-cholestandien-3-ol
provitamin-d3
17-(1,5-dimethylhexyl)-10,13-dimethyl-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol
DTXSID20861933
(3beta)-7-dehydro cholesterol
5,7-cholestadien-3beta-ol monohydrate
(3s,9s,10r,13r,14r,17r)-10,13-dimethyl-17-((r)-6-methylheptan-2-yl)-2,3,4,9,10,11,12,13,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-ol ,
Q139350
CS-0059496
HY-113279
CCG-268465
7-dehydrocholesterol (provitamin d3)
?7-dehydrocholesterol

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" Chronic dosing of vitamin D-deficient rats with 1,25-dihydroxyvitamin D3 caused a 4-fold increase in skin 7-dehydrocholesterol content."( 1,25-Dihydroxyvitamin D3 stimulated increase of 7,8-didehydrocholesterol levels in rat skin.
DeLuca, HF; Esvelt, RP; Sar, M; Stumpf, WE; Wichmann, JK; Yoshizawa, S; Zurcher, J, 1980
)
0.47
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
3beta-sterolA sterol in which the hydroxy group at position 3 has beta- configuration.
cholestanoidAny steroid based on a cholestane skeleton and its derivatives.
Delta(5),Delta(7)-sterolAny sterol containing two double bonds between positions 5-6 and 7-8.
3beta-hydroxy-Delta(5)-steroidAny 3beta-hydroxy-steroid that contains a double bond between positions 5 and 6.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (51)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Kandutsch-Russell pathway410
Vitamin D (calciferol) metabolism1210
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Steroids metabolism ( Steroids metabolism )1627
NADP+ + Cholesterol = NADPH + 7-Dehydro-cholesterol ( Steroids metabolism )14
Vitamin D-sensitive calcium signaling in depression213
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Kandutsch-Russell Pathway (Cholesterol Biosynthesis)930
Molting Hormone Biosynthesis821
cholesterol biosynthesis I428
cholesterol biosynthesis (plants)1417
cholesterol biosynthesis (plants, early side-chain reductase)117
Cholesterol biosynthesis with skeletal dysplasias014
7-oxo-C and 7-beta-HC pathways1513
Non-classical role of vitamin D86
Cholesterol synthesis disorders015
Cholesterol biosynthesis pathway in hepatocytes1137
cholesterol biosynthesis II (via 24,25-dihydrolanosterol)937
cholesterol biosynthesis I944
superpathway of cholesterol biosynthesis2178
Biosynthesis and regulation of nematode bile acids05
Vitamin D metabolism19
Biochemical pathways: part I0466
Vitamins A and D - action mechanisms09
Oxysterols derived from cholesterol3831
Sterols biosynthesis pathway015
Cholesterol biosynthesis I118
Cholesterol biosynthesis II (via 24,25-dihydrolanosterol)117

Protein Targets (1)

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (28)

Processvia Protein(s)Taxonomy
negative regulation of DNA-templated transcriptionVitamin D3 receptorHomo sapiens (human)
negative regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
cell morphogenesisVitamin D3 receptorHomo sapiens (human)
skeletal system developmentVitamin D3 receptorHomo sapiens (human)
calcium ion transportVitamin D3 receptorHomo sapiens (human)
intracellular calcium ion homeostasisVitamin D3 receptorHomo sapiens (human)
lactationVitamin D3 receptorHomo sapiens (human)
negative regulation of cell population proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of gene expressionVitamin D3 receptorHomo sapiens (human)
negative regulation of keratinocyte proliferationVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D 24-hydroxylase activityVitamin D3 receptorHomo sapiens (human)
positive regulation of bone mineralizationVitamin D3 receptorHomo sapiens (human)
phosphate ion transmembrane transportVitamin D3 receptorHomo sapiens (human)
bile acid signaling pathwayVitamin D3 receptorHomo sapiens (human)
mRNA transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
positive regulation of keratinocyte differentiationVitamin D3 receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIVitamin D3 receptorHomo sapiens (human)
decidualizationVitamin D3 receptorHomo sapiens (human)
intestinal absorptionVitamin D3 receptorHomo sapiens (human)
apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
positive regulation of apoptotic process involved in mammary gland involutionVitamin D3 receptorHomo sapiens (human)
regulation of calcidiol 1-monooxygenase activityVitamin D3 receptorHomo sapiens (human)
mammary gland branching involved in pregnancyVitamin D3 receptorHomo sapiens (human)
vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
positive regulation of vitamin D receptor signaling pathwayVitamin D3 receptorHomo sapiens (human)
response to bile acidVitamin D3 receptorHomo sapiens (human)
multicellular organism developmentVitamin D3 receptorHomo sapiens (human)
cell differentiationVitamin D3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (12)

Processvia Protein(s)Taxonomy
DNA-binding transcription factor activityVitamin D3 receptorHomo sapiens (human)
vitamin D response element bindingVitamin D3 receptorHomo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificVitamin D3 receptorHomo sapiens (human)
DNA bindingVitamin D3 receptorHomo sapiens (human)
nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
protein bindingVitamin D3 receptorHomo sapiens (human)
zinc ion bindingVitamin D3 receptorHomo sapiens (human)
bile acid nuclear receptor activityVitamin D3 receptorHomo sapiens (human)
nuclear retinoid X receptor bindingVitamin D3 receptorHomo sapiens (human)
calcitriol bindingVitamin D3 receptorHomo sapiens (human)
lithocholic acid bindingVitamin D3 receptorHomo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingVitamin D3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
nucleusVitamin D3 receptorHomo sapiens (human)
nucleusVitamin D3 receptorHomo sapiens (human)
nucleoplasmVitamin D3 receptorHomo sapiens (human)
cytosolVitamin D3 receptorHomo sapiens (human)
RNA polymerase II transcription regulator complexVitamin D3 receptorHomo sapiens (human)
chromatinVitamin D3 receptorHomo sapiens (human)
receptor complexVitamin D3 receptorHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID1907711Antagonist activity at VDR LBD (unknown origin) transfected in HEK-293T cells assessed as inhibition of 1,25(OH)2D3-induced receptor transactivation incubated for 16 hrs by Bright-Glo luciferase assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
AID1907713Antagonist activity at PPAR-gamma LBD (unknown origin) using Texas red-labeled DRIP-2 as substrate upto 100 uM incubated for 2 hrs in presence of rosiglitazone by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
AID1907709Antagonist activity at VDR LBD (unknown origin) using Alexa Fluor 647-labeled SRC2-3 as substrate incubated for 2 hrs in presence of calcitriol by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
AID603957Octanol-water partition coefficient, log P of the compound2008European journal of medicinal chemistry, Apr, Volume: 43, Issue:4
QSPR modeling of octanol/water partition coefficient for vitamins by optimal descriptors calculated with SMILES.
AID1768118Agonist activity at RORalpha in mouse NIH3T3 cells at 1 to 1000 uM incubated for 24 hrs by luminescence based assay2021Journal of natural products, 07-23, Volume: 84, Issue:7
Withanolide Derivative 2,3-Dihydro-3β-methoxy Withaferin-A Modulates the Circadian Clock via Interaction with RAR-Related Orphan Receptor α (RORa).
AID1907710Agonist activity at VDR LBD (unknown origin) using Alexa Fluor 647-labeled SRC2-3 as substrate incubated for 2 hrs by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
AID1907714Agonist activity at PPAR-gamma LBD (unknown origin) using Texas red-labeled DRIP-2 as substrate upto 100 uM incubated for 2 hrs by fluorescence polarization assay2022Journal of medicinal chemistry, 04-28, Volume: 65, Issue:8
Identification of a Vitamin-D Receptor Antagonist, MeTC7, which Inhibits the Growth of Xenograft and Transgenic Tumors
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (416)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (15.63)18.7374
1990's99 (23.80)18.2507
2000's96 (23.08)29.6817
2010's133 (31.97)24.3611
2020's23 (5.53)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 60.72

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index60.72 (24.57)
Research Supply Index6.07 (2.92)
Research Growth Index4.71 (4.65)
Search Engine Demand Index102.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (60.72)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials5 (1.17%)5.53%
Reviews34 (7.98%)6.00%
Case Studies44 (10.33%)4.05%
Observational0 (0.00%)0.25%
Other343 (80.52%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Investigating the Effects of Hydroxyvitamin D3 Versus Vitamin D3 on Clinical, and Radiologic Progress and Th17/Tregs Balance in MS Patients: A Randomized, Clinical Trial- a Pilot Study [NCT05340985]Phase 454 participants (Anticipated)Interventional2022-07-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]